IXICO

Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study

Retrieved on: 
Wednesday, February 28, 2024
Eli Lilly, African Americans, Merck, IXICO, Person, Research, Collaborative writing, Blood, AbbVie, Diagnosis, Volunteering, Digital technology, Roche, University, Biomarker, GAP, Journal, Disease, Alzheimer's Drug Discovery Foundation, White Americans, Brain, Amyloid plaques, PET, Biogen, Medical imaging

These findings will enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s disease and speed enrollment into clinical trials.

Key Points: 
  • These findings will enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s disease and speed enrollment into clinical trials.
  • GAP is proud that we succeeded in ensuring that the participants in this study reflected the diverse underrepresented populations afflicted with dementia.
  • With the recent approval of disease-modifying Alzheimer’s treatments, there is a growing need to simplify and accelerate an accurate diagnosis.
  • Dr. Richard Mohs observed that “This paper moves the field ahead in simplifying the diagnosis of Alzheimer’s disease.

Global Clinical Trial Imaging Market Size & Trends Analysis Report 2024-2030 - Market to Reach $1.97 Billion by 2030, Propelled by Advances in R&D - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 27, 2023
Health, Clinical Trials, Clutch (eggs), MRI, X-ray, Biotechnology, Research, EMA, FDA, Prevalence, Conditional sentence, OCT, Clinical trial, Cancer, USD, Patent, Optical coherence tomography, IXICO, ChromeOS, Biomarker, Investment, Safety, Medical imaging

The "Global Clinical Trial Imaging Market Size, Share & Trends Analysis Report by Service (Clinical Trial Design & Consultation Services, Reading & Analytical Services), End-use, Application, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Trial Imaging Market Size, Share & Trends Analysis Report by Service (Clinical Trial Design & Consultation Services, Reading & Analytical Services), End-use, Application, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global clinical trial imaging market size is expected to reach USD 1.97 billion by 2030, registering a CAGR of 7.60% during the forecast period, according to the report.
  • Increasing research and development spending to discover new drugs and therapies to treat chronic diseases is propelling the industry growth.
  • The need for clinical trial imaging is rapidly increasing in all phases of trials.

Global Imaging CRO Market to Expand as Clinical Trials Skyrocket and Demand for Medical Imaging Surges in 2023-2027

Retrieved on: 
Wednesday, August 30, 2023
Abbott, Biotechnology, Clinical trial, ICON, Research, Automation, Radiology, Clinical research associate, MUFG Americas Holdings Corporation, Application, OCT, Labcorp, IXICO, Parexel, Growth, FDA, ICON PLC, Medical imaging, Fine chemical

The global imaging clinical research organization (CRO) market is poised for impressive growth in the forecast period of 2023-2027.

Key Points: 
  • The global imaging clinical research organization (CRO) market is poised for impressive growth in the forecast period of 2023-2027.
  • A surge in clinical research has led to a significant increase in clinical trials, propelling the imaging CRO market.
  • Clinical trials are now empowered by Imaging Clinical Research Organizations, delivering invaluable insights across industries such as medical devices, biotech, and pharmaceuticals.
  • The importance of medical imaging in these trials is undeniable, with clinical trial numbers nearly doubling from 2010 to 2020, as reported by Keosys Medical Imaging.

Clinical Trial Imaging Market worth $1.9 billion | MarketsandMarkets

Retrieved on: 
Friday, August 18, 2023
Well, ICON PLC, Subjectivity, ICON, Incidence, Magnetic resonance imaging, Translational research, Conditional sentence, Digital, Health, Neurology, Clinical, Software, CT, CVS, Infection, HIV disease progression rates, Molecular Probes, Safety, Endocrinology, Leo Pharma, Echocardiography, Biotechnology, Cancer, Radiopharmaceutical, IXICO, Drug, Partnership, Drug development, Clinical trial, PET, We Are One (global collaboration song), Cardiology, Pharmaceutical industry, Medical imaging, Medical device

The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022

Key Points: 
  • The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022
    Based on product, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2022
    Based on therapeutic area, the clinical trial imaging market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area.
  • Clinical Trial Imaging Market Dynamics:
    Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
    The major players operating in this market are ICON plc.

Clinical Trial Imaging Market worth $1.9 billion | MarketsandMarkets

Retrieved on: 
Friday, August 18, 2023
Well, ICON PLC, Subjectivity, ICON, Incidence, Magnetic resonance imaging, Translational research, Conditional sentence, Digital, Health, Neurology, Clinical, Software, CT, CVS, Infection, HIV disease progression rates, Molecular Probes, Safety, Endocrinology, Leo Pharma, Echocardiography, Biotechnology, Cancer, Radiopharmaceutical, IXICO, Drug, Partnership, Drug development, Clinical trial, PET, We Are One (global collaboration song), Cardiology, Pharmaceutical industry, Medical imaging, Medical device

The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022

Key Points: 
  • The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022
    Based on product, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2022
    Based on therapeutic area, the clinical trial imaging market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area.
  • Clinical Trial Imaging Market Dynamics:
    Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
    The major players operating in this market are ICON plc.

Getting Neuroimaging Right -- How to Succeed in Neurodegenerative Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, December 1, 2022
Doctor of Philosophy, Success, Senior, Culminating project, Patient, Neuroimaging, Clinical trial, Food, Pharmaceutical industry, Medical imaging, IXICO

TORONTO, Dec. 1, 2022 /PRNewswire-PRWeb/ -- An undisputed fact is that clinical trial delays are very costly. Any strategies that accelerate start-up are key to a study's success in achieving timelines and expected budget. However, these drivers should not challenge the ultimate key objective of obtaining high-quality data without over-burdening the sites or the participants. In this webinar, the featured speakers will provide insights on how to address common challenges in neuroimaging studies.

Key Points: 
  • TORONTO, Dec. 1, 2022 /PRNewswire-PRWeb/ -- An undisputed fact is that clinical trial delays are very costly.
  • In this webinar, the featured speakers will provide insights on how to address common challenges in neuroimaging studies.
  • Register today to learn more about getting neuroimaging right and succeeding in neurodegenerative clinical trials.
  • For more information, or to register for this event, visit Getting Neuroimaging Right How to Succeed in Neurodegenerative Clinical Trials .

Current and Emerging Biomarkers to Advance Clinical Research in Parkinson's Disease, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, August 22, 2022
Associate Director of National Intelligence and Chief Information Officer, Food, Research, Doctor of Philosophy, LabCorp, MicroRNA, Magnetic resonance imaging, Mirna, MD, Biomarker, Parkinson's disease, MRI, Industry, Neurodegeneration, Medical imaging, IXICO

TORONTO, Aug. 22, 2022 /PRNewswire-PRWeb/ -- Parkinson's disease biomarker research continues to advance with the objectives of enabling earlier detection of neurodegeneration, elucidating disease mechanisms, identifying potential therapeutic targets as well as monitoring disease progression. While many promising biomarkers have been proposed, the ideal biomarker — with adequate sensitivity or specificity — remains elusive.

Key Points: 
  • Attendees will hear about emerging approaches for Parkinson's disease biomarkers, such as advanced magnetic resonance imaging (MRI).
  • The featured speakers will discuss how fluid and imaging biomarkers can impact study design and patient selection in Parkinson's disease clinical trials.
  • Join this webinar to learn how fluid and imaging biomarkers can impact study design and patient selection in Parkinson's disease clinical trials.
  • For more information, or to register for this event, visit Current and Emerging Biomarkers to Advance Clinical Research in Parkinson's Disease.

Global Clinical Trial Imaging Market Research Report 2022-2030 - Major Players are Developing Their CTI Services for Oncology, Neurology, and Musculoskeletal Applications - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 2, 2022
Health, Clinical Trials, Optical coherence tomography, Conditional sentence, Biomarker, Time, Research, Biotechnology, Parexel, EMA, ICON, Patent, USD, Disease, Investment, Method, FDA, Workflow, CT, X-ray, Neurology, Data management, Cros, Tata Consultancy Services, Clinical trial, OCT, Particle-size distribution, IXICO, Application, Education, Communities and Justice Directorates, MRI, CAGR, Safety, Medical imaging, Ultrasound

The "Clinical Trial Imaging Market Size, Share & Trends Analysis Report by Services (Clinical Trial Design and Consultation Services, Reading and Analytical Services), by End Use, by Application, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Trial Imaging Market Size, Share & Trends Analysis Report by Services (Clinical Trial Design and Consultation Services, Reading and Analytical Services), by End Use, by Application, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global clinical trial imaging market is expected to reach USD 1.97 billion by 2030, exhibiting a CAGR of 8.7%.
  • Market players provide analytical testing services, pharmacokinetic, reading, and pharmacodynamics services for enhanced clinical development.
  • Market players such as ICON, Bioclinica, Navitas Life Sciences, and Paraxel International are developing their clinical trial imaging services for these applications.

Brain Modalities and Software Market To Reach $23,195.6 Million by 2030, says P&S Intelligence

Retrieved on: 
Wednesday, May 4, 2022
Radiology, Rehabilitation, Population, Lists of diseases, Projection, Automation, APAC, MRI, Deep learning, General Electric Company, Software, Physician, CT, FDA, Person, Diagnosis, Teleradiology, IXICO, Canon Inc., Swoop, Fujifilm, MEA, LATAM, Method, Classification, Health Canada, CAGR, Intelligence, Awareness, AI, PET, Medical imaging, Medical device

NEW YORK, May 4, 2022 /PRNewswire/ -- In 2021, the global brain modalities and software market was valued at $13,343.3 million, which is set to reach $23,195.6 million by 2030, at a CAGR of 5.2% during 20212030, according to P&S Intelligence.

Key Points: 
  • NEW YORK, May 4, 2022 /PRNewswire/ -- In 2021, the global brain modalities and software market was valued at $13,343.3 million, which is set to reach $23,195.6 million by 2030, at a CAGR of 5.2% during 20212030, according to P&S Intelligence.
  • However, although software solutions provide value to standalone imaging modalities, in terms of numerical evaluations, diagnostic accuracy, and precision, software adoption in the LATAM and MEA regions has been slow, which will impel brain modalities and software market players to aggressively market their offerings here.
  • Moreover, all hardware includes software as complementary, which is why the demand for additional software only arises during system upgradation.
  • APAC is a rapidly growing brain modalities and software market, with a CAGR of roughly 7% predicted over the projection period.

Brain Modalities and Software Market To Reach $23,195.6 Million by 2030, says P&S Intelligence

Retrieved on: 
Wednesday, May 4, 2022
Radiology, Rehabilitation, Population, Lists of diseases, Projection, Automation, APAC, MRI, Deep learning, General Electric Company, Software, Physician, CT, FDA, Person, Diagnosis, Teleradiology, IXICO, Canon Inc., Swoop, Fujifilm, MEA, LATAM, Method, Classification, Health Canada, CAGR, Intelligence, Awareness, AI, PET, Medical imaging, Medical device

NEW YORK, May 4, 2022 /PRNewswire/ -- In 2021, the global brain modalities and software market was valued at $13,343.3 million, which is set to reach $23,195.6 million by 2030, at a CAGR of 5.2% during 20212030, according to P&S Intelligence.

Key Points: 
  • NEW YORK, May 4, 2022 /PRNewswire/ -- In 2021, the global brain modalities and software market was valued at $13,343.3 million, which is set to reach $23,195.6 million by 2030, at a CAGR of 5.2% during 20212030, according to P&S Intelligence.
  • However, although software solutions provide value to standalone imaging modalities, in terms of numerical evaluations, diagnostic accuracy, and precision, software adoption in the LATAM and MEA regions has been slow, which will impel brain modalities and software market players to aggressively market their offerings here.
  • Moreover, all hardware includes software as complementary, which is why the demand for additional software only arises during system upgradation.
  • APAC is a rapidly growing brain modalities and software market, with a CAGR of roughly 7% predicted over the projection period.